secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105306
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months
--------------------------------------------------------------------------------

- Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
- Shares priced at 98% of lowest 3-day VWAP; Yorkville capped at 4.99% beneficial ownership.
- Commitment fee of 1% paid in shares (half immediately, half at 6 months); structuring fee $25k.
- Proceeds for working capital, debt repayment, and leronlimab PD-L1 program development.
- No warrants or derivatives; registration statement to be filed for resale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000110465925105306/0001104659-25-105306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000110465925105306/cydy-20251103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer